Tango Therapeutics Reports $379.8 M Cash Runway, Q1 Net Loss of $45.5 M
Tango Therapeutics closed Q1 2026 with $379.8 million cash runway into 2028 and logged a $45.5 million net loss ($0.32 per share) on $33.5 million R&D and $15.2 million G&A spend. Its phase 1/2 vopimetostat combinations in MTAP-deleted pancreatic and lung cancers continue, with initial data and TNG456 glioblastoma results due in 2026.
1. Financial Results
As of March 31, 2026, the company held $379.8 million in cash, cash equivalents and marketable securities, providing runway into 2028. Collaboration revenue was $0 for the quarter versus $5.4 million year-ago, while R&D expenses of $33.5 million and G&A expenses of $15.2 million resulted in a net loss of $45.5 million ($0.32 per share).
2. Clinical Pipeline Updates
The Phase 1/2 study of vopimetostat in combination with RAS(ON) inhibitors is enrolling patients with second-line MTAP-deleted, RAS-mutant pancreatic and lung cancers, with early signs of tolerability and efficacy. Initial safety and efficacy data for combinations with daraxonrasib or zoldonrasib are expected in 2026, alongside vopimetostat monotherapy lung cancer results and initial TNG456 glioblastoma data to inform registrational strategy.
3. Corporate Developments and Upcoming Milestones
Two board members resigned as the company advances into late-stage development, and three executives—CFO Matthew Gall, Chief Development Operations Officer Yen-Ching Chua and SVP Janice Kapty, Ph.D.—joined leadership to support pivotal trials. Key upcoming milestones include initiating the vopimetostat plus ERAS-0015 combination study in second half 2026 and planning for a pivotal trial in first-line MTAP-deleted pancreatic cancer.